SUVEN · Health Care · 2026-08-21

Suven Life Sciences Ltd

7.0★★ GoodStrong +6.1Stage 2 · wk 13In scan: Prop Scan · Pullback HunterMARKET: BULL RISING · 2026-08-21
₹373.2
-0.12% today
₹10,544 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.

Visit company website →
ROE
-78.8%
Profit margin +0.0%
vs 52W High
-0.1%
₹126.7 lo₹373.6 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 13
1w13w26w
Week 13 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
75.2%
200 DMA: ₹213 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
1.31x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +1.0% vs MA50 +9.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #16 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #15 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 39w
S2 15w
S2 15w
S4 19w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 7w → S2 39w → S3 2w → S2 2w → S3 8w → S2 15w → S3 10w → S2 5w → S3 1w → S4 10w → S1 2w → S2 15w → S3 13w → S4 19w → S1 5w → S2 13w current
Total tracked: 167 weeks across 16 stage runs.
1M
+17.7%
3M
+40.6%
6M
+150.6%
YTD
+128.5%
1Y
+60.7%
Scan Membership
Prop Scan
Latest: 2026-08-21
Pullback Hunter
Latest: 2026-08-19
60 appearances in last 60 days. First seen: 2026-07-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 13 · Vol —x
2026-08-20S2
Wk 13 · Vol —x
2026-08-19S2
Wk 13 · Vol —x
2026-08-18S2
Wk 12 · Vol —x
2026-08-17S2
Wk 12 · Vol —x
2026-08-14S2
Wk 12 · Vol —x
2026-08-13S2
Wk 12 · Vol —x
2026-08-12S2
Wk 12 · Vol —x
2026-08-11S2
Wk 11 · Vol —x
2026-08-10S2
Wk 11 · Vol —x
2026-08-07S2
Wk 11 · Vol —x
2026-08-06S2
Wk 11 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹313
200 DMA
₹213
52W High
₹373.6
52W Low
₹126.7
5D Low
₹332.6
Resistance levels (recent highs)
20d High
₹373.6
60d High
₹373.6
120d High
₹373.6
250d High
₹373.6
Next resistance
+0.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.